Opinion
Video
Author(s):
Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following: